Clinical trials: T2D
Obesity, Type 2 Diabetes
Medication Following Bariatric Surgery for Type 2 Diabetes Mellitus
The aim of this study is to investigate the continued usage of standard diabetes medications in the post operative period following bariatric surgery to determine whether this approach may improve long term diabetes control.
- Trial name
- BY-PLUS (NCT04432025)
- Testing
- Bariatric surgery + goal directed medical therapy, Bariatric surgery
- Where
- Ireland
- Volunteers
- 150 people
- Sponsor
- Imperial College London
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Obesity, Overweight
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Study ASC30-302 (AURORA-2) is a Phase III, global, multicenter, randomized, double-blind, placebo-controlled study to investigate the long-term efficacy, safety, and tolerability of three maintenance doses of once-daily oral…
- Conditions
- Obesity, Overweight, Chronic Weight Management, Type 2 Diabetes Mellitus
- Trial name
- AURORA-2 (NCT07743450)
- Testing
- ASC30 tablets A1
- Where
- 135 sites in United States, Czechia and 4 more
- Volunteers
- 1,560 people
- Sponsor
- Ascletis Pharma (China) Co., Limited
Type 2 Diabetes Mellitus
A Study to Evaluate the PK/PD and Safety of TA-7284 in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
The purpose of this study is to evaluate the PK/PD and safety of TA-7284 in patients with type 2 diabetes mellitus who have moderate renal impairment.
- Trial name
- NCT01512849
- Testing
- TA-7284 Low, TA-7284 High
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes
A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours
The goal of this clinical research study is to learn about a new minimally invasive glucose monitoring device called Fluorescence Affinity Sensor (FAS).
- Trial name
- FAS (NCT01065948)
- Testing
- Subcutaneous glucose monitoring device
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- BioTex, Inc.
Diabetes Mellitus, Type 2
Nutritional Strategy for Glycemic Control in Patients With Type 2 Diabetes Mellitus (NUGLIC)
Adherence to a healthy dietary pattern is part of the self-care of patients with type 2 diabetes mellitus (T2DM), and may contribute substantially to therapeutic target goals and to a better quality of life as well.
- Trial name
- NCT03793855
- Testing
- Nutritional Strategy, Dietary Prescription
- Where
- 8 sites in Brazil
- Volunteers
- 370 people
- Sponsor
- Hospital do Coracao
Diabetes Mellitus
Duodenal Jejunal Bypass for Type 2 Diabetes (DJBD)
Study the effect of Duodenal jejunal bypass on human adults with type 2 diabetes.
- Trial name
- DJBD (NCT00487526)
- Testing
- duodenal jejunal bypass
- Where
- Dominican Republic
- Volunteers
- 50 people
- Sponsor
- Ferzli, George S., M.D. F.A.C.S.
Type 2 Diabetes Mellitus (T2DM), Necrotic Pulp
Photodynamic Therapy in Root Canal Treatment of T2DM Patients: Microbiome Analysis Via Next-Gen Sequencing
This clinical study investigates the effectiveness of antimicrobial photodynamic therapy (aPDT) as an additional disinfection method in root canal treatment of patients with Type 2 Diabetes Mellitus (T2DM) who have apical…
- Conditions
- Type 2 Diabetes Mellitus (T2DM), Necrotic Pulp, Apical Periodontitis
- Trial name
- NCT06931678
- Testing
- aPDT
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Saglik Bilimleri Universitesi
Type 2 Diabetes, Insulin Resistance
Metabolic Control Before and After Supplementation With Lactobacillus Reuteri DSM 17938 in Type 2 Diabetes Patients
Recent data suggest that the trillions of bacteria in the investigators gastrointestinal tracts (gut microbiota) can function as an environmental factor that modulates the amount of body fat.
- Trial name
- NCT01620125
- Testing
- Lactobacillus reuteri DSM 17938
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Vastra Gotaland Region
Prediabetes, Type 2 Diabetes (T2DM)
Vitamin D and Type 2 Diabetes - Treat-To-Target
This study tests whether taking a weekly dose of vitamin D, with the dose adjusted to reach a target blood vitamin D level, can help control blood sugar levels in adults at high risk of developing type 2 diabetes (prediabetes).
- Trial name
- D2d-TTT (NCT07448974)
- Testing
- Vitamin D (Cholecalciferol )
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Tufts Medical Center
Type 2 Diabetes
Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029
Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D745, D150 and D029 for Healthy Subjects in Fed State
- Trial name
- NCT05897216
- Testing
- CKD-383, CKD-501, D745, D150, D029
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 2 Diabetes
Effectiveness of an Online Self-management Intervention for Type 2 Diabetes Mellitus
This trial was designed to evaluate the effectiveness of the dialogue-based online intervention covivio, which was designed to improve diabetes self-management in patients with type 2 diabetes.
- Trial name
- OnSeT-2D (NCT05525117)
- Testing
- covivio (additional to treatment as usual), treatment as usual
- Where
- Germany
- Sponsor
- Gaia AG
Overweight, Obesity
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background…
- Trial name
- ENLIGHTEN-6 (NCT07392190)
- Testing
- Eloralintide
- Where
- 185 sites in United States, Australia and 12 more
- Volunteers
- 900 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2, Metabolic Syndrome
Randomized Control Trial for Overweight Employees in Worksites
Impact of lifestyle intervention in at-risk Asian Indians at worksite remains largely unexplored. The aim of this study was to assess impact of the multi-component interventions on body weight, body fat patterning and…
- Conditions
- Diabetes Mellitus, Type 2, Metabolic Syndrome, Lifestyle Risk Reduction
- Trial name
- NCT03249610
- Testing
- Lifestyle intervention
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Diabetes Foundation, India
Diabetes Mellitus, Type 2
Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition
Primary Objective: 1- Proportion of patients with mean daily glycemia <140mg/dL during the period of 7 days of treatment with glargine plus supplemental glulisine versus patients with glulisine sliding scale.
- Trial name
- NCT01081938
- Testing
- INSULIN GLARGINE, INSULIN GLULISINE
- Where
- 10 sites in Brazil
- Volunteers
- 15 people
- Sponsor
- Sanofi
Hyperglycemia, Hyperglucagonemia
Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
The incretin hormone glucagon-like peptide-1 (GLP-1) has known insulinotrophic and glucagonostatic properties. However, inpatients with type 2 diabetes mellitus (T2DM)it is shown, that the beta cell sensitivity towards GLP-1 is…
- Conditions
- Hyperglycemia, Hyperglucagonemia, Glucose Intolerance
- Trial name
- NCT00862589
- Testing
- GLP-1 infusion
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University Hospital, Gentofte, Copenhagen
Genetics Disease, Type2 Diabetes
Effects of Sitagliptin in Individuals With Genetically Decreased DPP4
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a…
- Conditions
- Genetics Disease, Type2 Diabetes, Heart Failure
- Trial name
- NCT04323189
- Testing
- Sitagliptin 100mg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04537637)
- Testing
- Oral Semaglutide
- Where
- 2 sites in Denmark
- Volunteers
- 99 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulin Glulisine in Adult Subjects With Type 2 Diabetes Receiving Insulin Glargine as Basal Insulin
The purpose of this study is to compare the change in glycemic control, as measured by hemoglobin A1c (HbA1c) from baseline to study week 24, in subjects receiving insulin glulisine as mealtime insulin following a variable bolus…
- Trial name
- NCT00135057
- Testing
- insulin glulisine, insulin glargine
- Where
- United States
- Volunteers
- 281 people
- Sponsor
- Sanofi